Evaluation of the safety and effectiveness of remidazolam besylate combined with esmketamine in the treatment of painless enteroscopy

Anesthesiology

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066994

Enrollment

Unknown

Registered

2022-12-23

Start date

2022-12-30

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology

Interventions

Group PE:Propofol combined with esketamine

Group RE:Remazolam besylate combined with esketamine

Eligibility

Sex/Gender

All

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 35 to 65 years; American Society of anesthesiologists (ASA) class I-II.

Exclusion criteria

Exclusion criteria: Known local anesthetic allergy history (remazolam besylate, esmketamine, dexmedetomidine, midazolam, propofol); Chronic renal failure (glomerular filtration rate 30 kg ? m – 2); Allergic to the drugs used in the study; The operation time was shorter than 20 min.

Design outcomes

Primary

Measure	Time frame
Operation completion success rate;	—

Secondary

Measure	Time frame
General information of patients;Hemodynamics;Intraoperative time index;Intraoperative drug dosage and infusion volume;Average oxygen saturation, minimum oxygen saturation, number of rescuers;Patient and physician satisfaction;	—

Countries

China

Contacts

Public Contactliwei

Inner Mongolia Erdos Central Hospital

732719139@qq.com15204778880

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026